| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Aprea Therapeutics Inc (NASDAQ: APRE)
APRE Technical Analysis
5
| As on 9th Jun 2023 APRE STOCK Price closed @ 3.53 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.30 & Strong Buy for SHORT-TERM with Stoploss of 2.30 we also expect STOCK to react on Following IMPORTANT LEVELS. |
APRESTOCK Price
| Open | 3.67 | Change | Price | % |
| High | 3.68 | 1 Day | 0.05 | 1.44 |
| Low | 3.45 | 1 Week | -0.32 | -8.31 |
| Close | 3.53 | 1 Month | -0.44 | -11.08 |
| Volume | 10214 | 1 Year | 0.19 | 5.69 |
| 52 Week High 9.48 | 52 Week Low 0.32 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| APRE Daily Charts |
APRE Intraday Charts |
Whats New @ Bazaartrend |
APRE Free Analysis |
|
|
APRE Important Levels Intraday
| RESISTANCE | 3.97 |
| RESISTANCE | 3.83 |
| RESISTANCE | 3.74 |
| RESISTANCE | 3.66 |
| SUPPORT | 3.40 |
| SUPPORT | 3.32 |
| SUPPORT | 3.23 |
| SUPPORT | 3.09 |
APRE Forecast May 2024
| 4th UP Forecast | 5.82 |
| 3rd UP Forecast | 5.09 |
| 2nd UP Forecast | 4.63 |
| 1st UP Forecast | 4.18 |
| 1st DOWN Forecast | 2.88 |
| 2nd DOWN Forecast | 2.43 |
| 3rd DOWN Forecast | 1.97 |
| 4th DOWN Forecast | 1.24 |
APRE Weekly Forecast
| 4th UP Forecast | 4.65 |
| 3rd UP Forecast | 4.29 |
| 2nd UP Forecast | 4.07 |
| 1st UP Forecast | 3.85 |
| 1st DOWN Forecast | 3.21 |
| 2nd DOWN Forecast | 2.99 |
| 3rd DOWN Forecast | 2.77 |
| 4th DOWN Forecast | 2.41 |
APRE Forecast2024
| 4th UP Forecast | 23.38 |
| 3rd UP Forecast | 17.01 |
| 2nd UP Forecast | 13.08 |
| 1st UP Forecast | 9.14 |
| 1st DOWN Forecast | -2.08 |
| 2nd DOWN Forecast | -6.02 |
| 3rd DOWN Forecast | -9.95 |
| 4th DOWN Forecast | -16.32 |
Aprea Therapeutics Inc ( NASDAQ USA Symbol : APRE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
APRE Business Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts. Address: 535 Boylston Street, Boston, MA, United States, 02116
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service